Education
About Us
Working with TipRanks
Follow Us
Initiator Pharma A/S (SE:INIT)
:INIT
Top Page
Initiator Pharma A/S
(INIT)
Select Model
Select Model
Rating:47Neutral
Price Target:
kr3.00
▼(-1.32% Downside)
The score is primarily held back by weak financial performance—no revenue, ongoing losses, and continued cash burn despite some improvement in 2024. Technical indicators are neutral-to-mixed and provide only modest support, while valuation is difficult to assess due to negative earnings and no dividend yield data.
Initiator Pharma A/S (INIT) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr207.41M
Dividend YieldN/A
Average Volume (3M)133.41K
Price to Earnings (P/E)―
Beta (1Y)0.45
Revenue GrowthN/A
EPS GrowthN/A
CountrySE
Employees2
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.09
Shares Outstanding68,452,890
10 Day Avg. Volume157,519
30 Day Avg. Volume133,406
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.02
Price to Sales (P/S)0.00
P/FCF Ratio-0.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Initiator Pharma A/S Business Overview & Revenue Model
Company DescriptionInitiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. It develops IP2018, a monoamine reuptake inhibitor for the treatment of psychogenic erectile dysfunction; IPED2015 to treat patients suffering from organic erectile dysfunction; and IPTN2021 for targeting an orphan drug indication in severe neuropathic pain. The company's pre-clinical stage candidates include IPNP2015 for the treatment of chronic pain; and IPDP2015 for depression. Initiator Pharma A/S was incorporated in 2016 and is headquartered in Copenhagen, Denmark.
How the Company Makes Money
Initiator Pharma A/S Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -9.34M | -11.07K | -23.41K | -38.42K | -21.63K | -9.30K |
| EBITDA | -12.43M | -14.50K | -27.03K | -41.73K | -23.06K | -10.51K |
| Net Income | -10.54M | -12.93K | -22.87K | -38.45M | -21.06M | -8.70M |
Balance Sheet | ||||||
| Total Assets | 13.77M | 15.29M | 29.79M | 48.34M | 53.70M | 15.60M |
| Cash, Cash Equivalents and Short-Term Investments | 4.70M | 13.37M | 24.34M | 38.91M | 34.15M | 13.50M |
| Total Debt | 2.19M | 0.00 | 15.44M | 12.58M | 13.29M | 0.00 |
| Total Liabilities | 5.51M | 510.00K | 18.62M | 14.32M | 18.71M | 1.19M |
| Stockholders Equity | 8.27M | 14.78M | 11.16M | 34.02M | 34.99M | 14.41M |
Cash Flow | ||||||
| Free Cash Flow | -1.02M | -12.08M | -17.65M | -32.70M | -34.10M | -8.06M |
| Operating Cash Flow | -1.02M | -12.08M | -17.65M | -32.70M | -34.10M | -8.06M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | -17.00K | 0.00 | 0.00 |
| Financing Cash Flow | -108.81K | 1.11M | 2.87M | 37.48M | 54.94M | 14.01M |
Initiator Pharma A/S Peers Comparison
UnderperformOutperform
Sector (51)
SE:INIT
Initiator Pharma A/S
3.03
-4.22
-58.21%
SE:MVIR
Medivir AB
0.45
-2.54
-85.02%
DE:5IU
Isofol Medical AB
0.05
-0.12
-71.26%
DE:1XT
Xintela AB
0.01
-0.01
-44.00%
DE:99Z
Modus Therapeutics Holding AB
0.02
-0.03
-67.35%
DE:BTPC
Active Biotech AB
0.01
0.00
0.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.